

T: 0131-244 2528 0131-244 2375
E: irene.fazakerley@scotland.gsi.gov.uk
30 March 2011

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Chief Pharmacists NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

Dear Healthcare Professional,

DRUG ALERT NO 11 – CLASS 2

Please see the attached drug alert for onward transmission as below.

Please could all Directors of Pharmacy forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

1. Please could Medical Directors forward this alert to:-

- General Practitioners
- Relevant Clinics
- Chief Executives of NHS Boards

Thank you for your co-operation.

Yours sincerely

Leslie Smith
pp

IRENE FAZAKERLEY
Pharmacy Division

Safeguarding public health
Defective Medicines Report Centre
151 Buckingham Palace Road
London
SW1W 9SZ
Telephone +44 (0)20 3080 6574

MHRA

DRUG ALERT

CLASS 2 MEDICINES RECALL

Action within 48 Hours
PHARMACY LEVEL RECALL

Date: 30 March 2011

EL (11)A/11

Our Ref: MDR 43-03/11

Dear Healthcare Professional,

CHAUVIN PHARMACEUTICALS LIMITED

Minims Dexamethasone sodium phosphate
0.1%w/v Eye Drops, Solution (Bausch & Lomb
livery)

PL 00033/0153

Batch Number	Expiry Date	Pack Size	First Distributed
F23832	Jan 2012	1 x 20	25 Feb 2011

Bausch & Lomb is recalling the above batch because of a packaging error. The clear film overwrap of each individual unit is printed incorrectly with Chloramphenicol 0.5% w/v instead of Dexamethasone 0.1% w/v. The printing on the outer packaging is correct as is the Patient Information Leaflet contained in packs from this batch.

Pharmacists are asked to quarantine affected stock and contact the wholesaler from which it was obtained to arrange uplift and replacement. For stock enquiries, please contact Bausch & Lomb Customer Services Team on 0208 7812991

For medical information enquiries, please contact Professional Information on 01748 828 864.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to general practitioners, community pharmacists and relevant clinics.

Yours faithfully

Alison Bunce, Pharmaceutical Assessor, DMRC

MHRA Distribution:

Regional Contacts for NHS Trusts and Provider Units
Chief Pharmacists: England, Scotland, Wales, Northern Ireland
Prison Health Policy Unit (DH)
Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special Hospitals
Healthcare Commission for distribution to Independent Health Care Establishments
Primary Care Trusts (England)

Medicines and Healthcare products Regulatory Agency (MHRA)
151 Buckingham Palace Road London SW1W 9SZ UK
T 020 3080 6000 www.mhra.gov.uk

An executive agency of the Department of Health